Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow Chinese firm Nanjing Kangerjia Medical Technology Co., Ltd to collaboratively develop modified drugs aimed at treating sleep disorders. This strategic alliance combines Triastek’s expertise in 3D printing technology with Kangerjia’s commercialization experience in the field of sleep and neurological disorders.
Triastek will apply its proprietary Melt Extrusion Deposition (MED) 3D printing technology to design innovative dosage forms for medications targeting sleep disorders. The unique microstructure delivery technology provided by 3D printing is expected to yield product pharmacokinetic curves that align more closely with the clinical needs of patients, enhancing therapeutic outcomes. Additionally, Triastek’s digital development methods and continuous production techniques are set to expedite the development and commercialization timeline of these pharmaceutical products.
Leveraging Kangerjia’s extensive experience in commercializing products for sleep disorders and other mental/neurological conditions, the partnership aims to effectively bring these new drug formulations to market. Looking ahead, the companies plan to explore further development opportunities in the realms of psychotropic drugs and mental/neurological disorder treatments.- Flcube.com
